相关实验视频

Updated: Jan 16, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

对IKKβ和NR4A1进行双重向,用于AML治疗

Chandra K Maharjan, Yi Liu, Yufeng Xiao

bioRxiv : the preprint server for biology

|October 3, 2025

概括

研究人员开发了一种针对IKKβ和NR4A1的新型PROTAC药物,用于治疗急性髓性白血病 (AML). 这种新疗法有效降解这些蛋白质,在临床前模型中显示出没有常见副作用的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

急性髓性白血病 (AML) 是一种具有不良治疗结果的侵袭性血液癌症.
现有的AML治疗方法的疗效有限,副作用很大.
IKKβ和NR4A1被确定为AML进展的关键驱动因素.

研究的目的:

确定AML的新型治疗点.
开发一种蛋白质溶解向喜梅拉 (PROTAC) 药物,具有针对IKKβ和NR4A1.1的双重降解活性.
在AML模型中评估开发的PROTAC的疗效和安全性.

主要方法:

设计,合成和验证基于赛拉斯特的PROTACs.
评估PROTAC介导的IKKβ和NR4A1在AML细胞系和原始细胞中的降解.
在AML的KMT2A::MLLT3小鼠模型中评估PROTAC的疗效.
涉及cereblon (CRBN) E3结合酶和蛋白质体降解的机制研究.

主要成果:

一种主要的PROTAC化合物A9有效降解IKKβ和NR4A1.1.
A9对各种AML细胞系和原发性人类AML细胞表现出强大的细胞毒性.
在临床前的小鼠模型中,A9治疗减轻了AML疾病的进展.
PROTAC A9不会诱导中性恋,这是IKKβ抑制剂的常见副作用.

结论:

IKKβ和NR4A1是AML病变发生的关键媒介.
一种基于的新型PROTAC (A9) 通过同时降解IKKβ和NR4A1.1,为AML提供了一个有前途的治疗策略.
这种双重向的PROTAC方法可以克服现有疗法的局限性,并为难以治疗的AML提供新的治疗选择.

更多相关视频

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...